{"id":"NCT02609828","sponsor":"Pfizer","briefTitle":"Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-28","primaryCompletion":"2020-09-17","completion":"2021-06-25","firstPosted":"2015-11-20","resultsPosted":"2023-01-20","lastUpdate":"2023-02-16"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bone Metastasis","Cancer Pain"],"interventions":[{"type":"DRUG","name":"Tanezumab","otherNames":["PF-04383119"]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.","primaryOutcome":{"measure":"Change From Baseline in the Daily Average Pain Intensity Numerical Rating Score (NRS) in the Index Bone Metastasis Cancer Pain Site at Week 8","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-1.25,"sd":0.35},{"arm":"Tanezumab 10 mg","deltaMin":null,"sd":null},{"arm":"Tanezumab 10/20 mg","deltaMin":null,"sd":null},{"arm":"Tanezumab 20 mg","deltaMin":-2.03,"sd":0.35}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0381"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":30},"locations":{"siteCount":89,"countries":["Argentina","Australia","Austria","Brazil","Chile","China","Czechia","Hungary","Israel","Japan","Poland","Romania","Slovakia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["37343145"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091061&StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%2C%20Placebo-controlled%2C%20Multicenter%20Study%20Of%20The%20Analgesic%20Efficacy%20And%20Safety%20Of%20The%20Subcutaneous%20Administration%20Of%20Tanezumab%20%28pf-04383119%29%20In%20Subjects%20With%20Cancer%20Pain%20Predominantly%20Due%20To%20Bone%20Metastasis%20Receiving%20Background%20Opioid%20Therapy"]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":73},"commonTop":["Anaemia","Arthralgia","Decreased appetite","Fatigue","Constipation"]}}